[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353913-105":59,"doc-detail-353913-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-cost-effectiveness-of-lung-cancer-screening-in-france-with-low-dose-computed-tomography","Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography","","Lung cancer ranks as the third most frequent cancer in France and carries a poor prognosis when detected at advanced stages. Low-dose computed tomography (LDCT) enables detection of earlier-stage disease, and blood-based biomarkers may improve screening selection or management of indeterminate lung nodules. This study uses a France-calibrated microsimulation model to compare no screening, biennial LDCT, LDCT with biomarkers, and biomarker-guided screening followed by LDCT. Screening eligibility is based on age 50–74 and smoking history, with 25% assumed participation, incorporating French health-system costs and 2.5% discounting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-cost-effectiveness-of-lung-cancer-screening-in-france-with-low-dose-computed-tomography/353913/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-cost-effectiveness-of-lung-cancer-screening-in-france-with-low-dose-computed-tomography/353913.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study objective regarding lung cancer screening in France?","Question",{"text":112,"@type":113},"To evaluate the efficacy and cost-effectiveness of lung cancer screening in the French context, including LDCT and potential blood-based biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which screening strategies were compared in the microsimulation model?",{"text":117,"@type":113},"Four strategies were compared: no screening, biennial LDCT, biennial LDCT followed by biomarkers, and biennial screening with biomarkers followed by LDCT.",{"name":119,"@type":110,"acceptedAnswer":120},"How are eligibility criteria and participation assumptions defined?",{"text":121,"@type":113},"Eligibility required age 50–74 and specific smoking history thresholds, and the model assumed a 25% participation rate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353913,1790496493,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Research  \npaper  \n273  \nEfficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography  \nHenri Leleua, Quentin Berkovitcha, Julia Bonastreb,c, Caroline Caramellad,e,Étienne Giroux-Leprieurf, Lucile Lefèvreg, Pernelle Lavaudh, Andreea Todeag, Marie Wislezi and Paul Hofmanj  \nLung cancer is the third most frequent cancer in France. It has a poor prognosis when patients are diagnosed at advanced stages. Low-dose computed tomography (LDCT) can detect early-stage cancer. In addition, blood-based biomarkers could help select patients for lung cancer screening or manage indeterminate lung nodules. The objective of this study is to assess the efficacy and cost-effectiveness of lung cancer screening in the French context including LDCT and biomarkers. Amicrosimulation model calibrated for France was used to compare four strategies: no screening, biennial LDCT, biennial LDCT followed by biomarkers, and biennial screening with biomarkers followed by LDCT. Screening eligibility included age (50–74) and smoking history (>15 cigarettes/day over 25 years, or 10 cigarettes/ day over 30 years, or former smokers who quit less than 10 years ago). A 25% participation rate was assumed. Direct medical costs were estimated from the perspective of the French health system. Cost and outcomes were discounted at 2.5%. Screening decreased lifetime  \nlung cancer mortality from 2 to 12% depending on the participation rate, leading to an increase in both life years and quality-adjusted life years (QALY). Considering cost effectiveness, LDCT screening was associated with an incremental cost-effectiveness ratio of €7629 per QALY  \nin comparison to the absence of screening. Sensitivity analyses were all favorable to LDCT-based screening strategies. Biennial LDCT screening could be an effective and cost-effective strategy in France even at a 25% participation rate. European Journal of Cancer Prevention 35: 273–280 Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc  \nEuropean Journal of Cancer Prevention 2026, 35:273–280  \nKeywords: biomarkers, cancer screening, low-dose computed tomography, lung cancer, smoking  \na Public Health Expertise, Paris, bBureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, cINSERM, Université Paris-Saclay, CESP U1018 Oncostat, labelisé Ligue contre le cancer, Villejuif, dRadiology Department, Groupe Hospitalier Paris Saint Joseph, Hôpital Marie Lannelongue, Le Plessis-Robinson, e BIOMAPS UMR 1281, Université Paris-Saclay, Inserm, CNRS, CEA, Paris, fDepartment of Respiratory Diseases and Thoracic Oncology, Université Paris-Saclay, UVSQ, EA 4340 BECCOH, APHP-Hôpital Ambroise Paré, Boulogne-Billancourt, gJanssen-Cilag, Issy-les-Moulineaux, Issy-les-Moulineaux, hDepartment of Medical Oncology, Gustave Roussy Cancer Center, University of Paris Saclay, Villejuif, iUnité d’Oncologie Thoracique, Service de Pneumologie, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Université, Paris and jIHU RespirERA, FHU OncoAge, Laboratoirede Pathologie Clinique et Expérimentale, BB-0033-00025, Hôpital Pasteur 1, Université Côte d’Azur, Nice, France  \nCorrespondence to Henri Leleu, MD, PhD, Public Health Expertise, 10  \nBoulevard de Sébastopol, Paris 75004, France  \nTel: +1 84170238; [e-mail: Henri.leleu@ph-expertise.com](e-mail: Henri.leleu@ph-expertise.com)[ ](e-mail: Henri.leleu@ph-expertise.com)[Received 9 January 2025 Accepted 29 March 2025](Received 9 January 2025 Accepted 29 March 2025) .  \nIntroduction  \nLung cancer is the third most frequent cancer in France. An estimated 46 363 patients were diagnosed in 2018 with an associated 33 117 deaths (Belot et al., 2008) . The risk of developing lung cancer is driven by age and smoking status, with smoking estimated to account for around 90% of all lung cancers in Europe and the US (Alberg et al., 2013; Coëtmeur et al., 2016; Siegel et al., 2019) .  \nHistorically, lung cancer had a poor prognosis, with an a","cbCaipeQZAIQxFgO","https://ap.wps.com/l/cbCaipeQZAIQxFgO","pdf",745515,"English","# Introduction\n## Clinical context and rationale for screening\n# Methods\n## Microsimulation model and strategy comparison\n## Eligibility criteria and cost assumptions\n## Discounting and outcomes\n# Results\n## Mortality reduction and QALY gains\n## Incremental cost-effectiveness and sensitivity analyses\n# Conclusions\n## Cost-effective LDCT screening under assumed participation","[{\"question\":\"What is the study objective regarding lung cancer screening in France?\",\"answer\":\"To evaluate the efficacy and cost-effectiveness of lung cancer screening in the French context, including LDCT and potential blood-based biomarkers.\"},{\"question\":\"Which screening strategies were compared in the microsimulation model?\",\"answer\":\"Four strategies were compared: no screening, biennial LDCT, biennial LDCT followed by biomarkers, and biennial screening with biomarkers followed by LDCT.\"},{\"question\":\"How are eligibility criteria and participation assumptions defined?\",\"answer\":\"Eligibility required age 50–74 and specific smoking history thresholds, and the model assumed a 25% participation rate.\"}]","Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography | PDF",1790107883,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b0e2c0bae0b03e6eff72ff0c06d24ba.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de8454ca68de1d17543803e3dcf1f592.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/921b3712c3eb1205852e75c783e1d0b0.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddd49909ab99a120158283f39a0b2e85.webp",980,1306]